134 related articles for article (PubMed ID: 38225603)
1. Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments.
Wang DX; Long JY; Li RZ; Zhang DL; Liu H; Liu J; Tian JC; Li H; Liu J; Zhao HT; Li T
Mol Cancer; 2024 Jan; 23(1):15. PubMed ID: 38225603
[TBL] [Abstract][Full Text] [Related]
2. Genomic alterations in KMT2 family predict outcome of immune checkpoint therapy in multiple cancers.
Zhang P; Huang Y
J Hematol Oncol; 2021 Mar; 14(1):39. PubMed ID: 33653367
[TBL] [Abstract][Full Text] [Related]
3. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
4. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
5. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.
Wang J; Xiu J; Baca Y; Battaglin F; Arai H; Kawanishi N; Soni S; Zhang W; Millstein J; Salhia B; Goldberg RM; Philip PA; Seeber A; Hwang JJ; Shields AF; Marshall JL; Astsaturov I; Craig Lockhart A; Gatalica Z; Michael Korn W; Lenz HJ
Oncogene; 2021 Jul; 40(30):4894-4905. PubMed ID: 34163031
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
[TBL] [Abstract][Full Text] [Related]
7. KMT2A/C mutations function as a potential predictive biomarker for immunotherapy in solid tumors.
Zhang R; Wu HX; Xu M; Xie X
Biomark Res; 2020 Dec; 8(1):71. PubMed ID: 33298164
[TBL] [Abstract][Full Text] [Related]
8. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers.
Zhang Z; Wu HX; Lin WH; Wang ZX; Yang LP; Zeng ZL; Luo HY
BMC Med; 2021 Feb; 19(1):26. PubMed ID: 33526018
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma.
Zhang W; Xia H; Yang R; Zhang Y; Zheng Q; Shang X; Liu N; Ma X; Wei C; Chen H; Mu X; Wang X; Liu Y
Front Immunol; 2022; 13():1030969. PubMed ID: 36426352
[TBL] [Abstract][Full Text] [Related]
10. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
Front Immunol; 2022; 13():991091. PubMed ID: 36248841
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer analysis of ARID family members as novel biomarkers for immune checkpoint inhibitor therapy.
Zhu Y; Yan C; Wang X; Xu Z; Lv J; Xu X; Yu W; Zhou M; Yue L
Cancer Biol Ther; 2022 Dec; 23(1):104-111. PubMed ID: 35239432
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
[TBL] [Abstract][Full Text] [Related]
13. ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma.
Zhang W; Shang X; Liu N; Ma X; Yang R; Xia H; Zhang Y; Zheng Q; Wang X; Liu Y
BMC Pulm Med; 2022 Dec; 22(1):483. PubMed ID: 36539782
[TBL] [Abstract][Full Text] [Related]
14. Association of ERCC family mutations with prognosis and immune checkpoint inhibitors response in multiple cancers.
Chen C; Liu H; Li Y; Liu J
Sci Rep; 2023 Aug; 13(1):13925. PubMed ID: 37626083
[TBL] [Abstract][Full Text] [Related]
15. Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers.
Wu HX; Chen YX; Wang ZX; Zhao Q; He MM; Wang YN; Wang F; Xu RH
J Immunother Cancer; 2019 Oct; 7(1):264. PubMed ID: 31623662
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive molecular analysis identifies RET alterations association with response of ICIs in multi-immunotherapy cohorts.
Long JY; Li RZ; Wang DX; Liu H; Tian J; Ding ZN; Yan LJ; Dong ZR; Hong JG; Tian BW; Han CL; Zhao HT; Li T
Int Immunopharmacol; 2024 Jan; 126():111281. PubMed ID: 38061115
[TBL] [Abstract][Full Text] [Related]
17. Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.
Long J; Wang D; Yang X; Wang A; Lin Y; Zheng M; Zhang H; Sang X; Wang H; Hu K; Zhao H
BMC Med; 2021 Jul; 19(1):154. PubMed ID: 34284787
[TBL] [Abstract][Full Text] [Related]
18. Correlation of KMT2 family mutations with molecular characteristics and prognosis in colorectal cancer.
Liao C; Huang W; Lin M; Li H; Zhang Z; Zhang X; Chen R; Huang M; Yu P; Zhang S
Int J Biol Markers; 2022 Jun; 37(2):149-157. PubMed ID: 35505597
[TBL] [Abstract][Full Text] [Related]
19. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
Front Immunol; 2021; 12():638763. PubMed ID: 34305884
[TBL] [Abstract][Full Text] [Related]
20. GRIN2A mutation is a novel indicator of stratifying beneficiaries of immune checkpoint inhibitors in multiple cancers.
Li GX; Chang RZ; Liu TT; Jin GN; Lu K; Yong TY; Li Z; Liu JH; Zhang B; Zhang WG; Ding ZY
Cancer Gene Ther; 2024 Apr; 31(4):586-598. PubMed ID: 38267623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
